

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Modern Chinese Medicine Group Co., Ltd.

現代中藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1643)

GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES

References are made to the announcements of Modern Chinese Medicine Group Co., Ltd. (the “**Company**”) dated 3 November 2023 and 24 November 2023 in relation to the major transaction regarding the Engineering Contract and delay in despatch of circular respectively (collectively the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless otherwise specified.

As set out in the Announcements, it was expected that the Circular would be despatched to the Shareholders on or before 24 November 2023. However, as additional time is required in finalising the certain information for inclusion in the Circular, the Company has applied for the Waiver. The Waiver has been granted by the Stock Exchange on 27 November 2023 and the expected despatch date of the Circular has been extended to a date on or before 31 December 2023.

The Stock Exchange may withdraw or change the Waiver if the situation changes.

By Order of the Board
Modern Chinese Medicine Group Co., Ltd.
Zhang Hongli
Executive Director

Hong Kong, 27 November 2023

As at the date of this announcement, the Board comprises three executive Directors, namely Ms. Zhang Hongli, Ms. Sun Xinlei and Ms. Jia Yanru; and three independent non-executive Directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.